Temozolomide and irinotecan combination chemotherapy in patients with a specific subgroup of colorectal cancer and with circulating tumor DNA positivity after standard post-operative treatment

Primary objectives: To assess the activity in terms of seroreversion of temozolomide and irinotecan (TEMIRI) consolidation regimen administered to patients with high-risk stage II (pT4) or III microsatellite stable, MGMT silenced CRC and positive post-adjuvant ctDNA after standard oxaliplatin-based adjuvant chemotherapy. Primary endpoints: The activity of TEMIRI will be measured as the rate of patients with post-treatment seroreversion and disease-free at 2 years.